Literature DB >> 22449375

Effect of ranolazine on rat intrarenal arteries in vitro.

Chun-Yu Deng1, Su-Juan Kuang, Fang Rao, Hui Yang, Xian-Hong Fang, Zhi-Xin Shan, Xiao-Hong Li, Zhi-Ling Zhou, Qiu-Xiong Lin, Min Yang, Shu-Lin Wu, Xi-Yong Yu, Shu-Guang Lin.   

Abstract

Ranolazine is mainly used to treat patients with chronic stable angina in clinical practice. However, ranolazine does not lower significantly systemic blood pressure. The direct effect of ranolazine on vascular tone remains unknown. In the present study, we investigated the vascular effects and mechanisms of action of ranolazine in isolated rat intrarenal arteries. Rings of intrarenal arteries were mounted in a small vessel myography using two stainless steel wires for the measurement of isometric tension. L-type Ca²⁺ currents were recorded in isolated single renal arterial smooth muscle cells using patch clamp techniques in whole-cell mode. Ranolazine induced concentration-dependent relaxations in rings contracted with phenylephrine, but ranolazine failed to cause any relaxation in rings pre-contracted by U46619, 5-HT or endothelin-1. Ranolazine also induced relaxations in norepinephrine pre-contracted rings. Yohimbine failed to induce relaxation in rings pre-contracted by norepinephrine. Propranolol did not affect ranolazine-induced relaxation but the relaxant effect of ranolazine was much less than that of prazosin. Ranolazine-induced relaxations were slight but significantly attenuated by endothelial denudation. Partial inhibition was observed in endothelium-intact arteries exposed to a combination of iberiotoxin and apamin. Ranolazine at higher concentration (>30 μM) inhibited Ca²⁺-induced contraction in a noncompetitive manner. Ranolazine reduced L-type Ca²⁺ currents at potentials between -30 and 50 mV in isolated renal artery myocytes. Therefore it can be said that ranolazine has significant α₁-adrenergic receptor and weak calcium channel antagonistic effects in rat intrarenal arteries.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22449375     DOI: 10.1016/j.ejphar.2012.03.010

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  7 in total

1.  Ranolazine inhibits voltage-gated mechanosensitive sodium channels in human colon circular smooth muscle cells.

Authors:  Leila Neshatian; Peter R Strege; Poong-Lyul Rhee; Robert E Kraichely; Amelia Mazzone; Cheryl E Bernard; Robert R Cima; David W Larson; Eric J Dozois; Crystal F Kline; Peter J Mohler; Arthur Beyder; Gianrico Farrugia
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2015-07-16       Impact factor: 4.052

2.  Ranolazine attenuated heightened plasma norepinephrine and B-Type natriuretic peptide-45 in improving cardiac function in rats with chronic ischemic heart failure.

Authors:  Guangqiu Feng; Yu Yang; Juan Chen; Zhiyong Wu; Yin Zheng; Wei Li; Wenxin Dai; Pin Guan; Chunrong Zhong
Journal:  Am J Transl Res       Date:  2016-02-15       Impact factor: 4.060

3.  Ranolazine recruits muscle microvasculature and enhances insulin action in rats.

Authors:  Zhuo Fu; Lina Zhao; Weidong Chai; Zhenhua Dong; Wenhong Cao; Zhenqi Liu
Journal:  J Physiol       Date:  2013-06-24       Impact factor: 5.182

4.  Antagonism of Nav channels and α1-adrenergic receptors contributes to vascular smooth muscle effects of ranolazine.

Authors:  Anne Virsolvy; Charlotte Farah; Nolwenn Pertuit; Lingyan Kong; Alain Lacampagne; Cyril Reboul; Franck Aimond; Sylvain Richard
Journal:  Sci Rep       Date:  2015-12-10       Impact factor: 4.379

5.  Diabetes mellitus aggravates ranolazine-induced ECG changes in rats.

Authors:  Habibeh Mashayekhi-Sardoo; Amir Hooshang Mohammadpour; Soghra Mehri; Hossein Kamali; Amirhossein Sahebkar; Mohsen Imenshahidi
Journal:  J Interv Card Electrophysiol       Date:  2021-06-21       Impact factor: 1.900

6.  The Evidence for Sparsentan-Mediated Inhibition of INa and IK(erg): Possibly Unlinked to Its Antagonism of Angiotensin II or Endothelin Type a Receptor.

Authors:  Tzu-Hsien Chuang; Hsin-Yen Cho; Sheng-Nan Wu
Journal:  Biomedicines       Date:  2021-12-31

Review 7.  Ranolazine: An Old Drug with Emerging Potential; Lessons from Pre-Clinical and Clinical Investigations for Possible Repositioning.

Authors:  Sarah Rouhana; Anne Virsolvy; Nassim Fares; Sylvain Richard; Jérôme Thireau
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-25
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.